Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The increasing complexity of the genetic landscape in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) presents a significant resource and physician training challenge. At least 10% of those diagnosed with ALS or FTD are known to carry an autosomal dominant genetic mutation. There is no consensus on what constitutes a positive family history, and ascertainment is unreliable for many reasons. However, symptomatic individuals often wish to understand as much as possible about the cause of their disease, and to share this knowledge with their family. While the right of an individual not to know is a key aspect of patient autonomy, and despite the absence of definitive therapy, many newly diagnosed individuals are likely to elect for genetic testing if offered. It is incumbent on the practitioner to ensure that they are adequately informed, counselled and supported in this decision.

Original publication

DOI

10.1136/jnnp-2017-315995

Type

Journal article

Journal

J Neurol Neurosurg Psychiatry

Publication Date

12/2017

Volume

88

Pages

1042 - 1044

Keywords

ALS, C9ORF, FRONTOTEMPORAL DEMENTIA, GENETICS, Amyotrophic Lateral Sclerosis, C9orf72 Protein, Frontotemporal Dementia, Genetic Testing, Humans, Reproducibility of Results